Enhancer mutations modulate the severity of chemotherapy-induced myelosuppression
Life Science AllianceUsing transcriptome and interactome maps with patients’ WGS, this research uncovers the role of noncoding mutations in the myelosuppression predisposition, advancing personalized cancer treatment. Non-small cell lung cancer is often diagnosed at advanced
Artemy Zhigulev +8 more
doaj +2 more sources
Association between Prognostic Nutritional Index and myelosuppression in gastric cancer patients undergoing chemotherapy: a retrospective cohort study [PDF]
Frontiers in NutritionObjectiveTo investigate the association between Prognostic Nutritional Index (PNI) and chemotherapy-induced myelosuppression in gastric cancer patients.MethodsThis retrospective cohort study analyzed 562 gastric cancer patients receiving chemotherapy at ...
Kexia Chen +6 more
doaj +2 more sources
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
Myelosuppression in Patients with Prolonged use of Piperacillin/Tazobactam [PDF]
, 2020 Objectives: The use of piperacillin-tazobactam in hospital acquired infections requiring long treatment periods maycause adverse effects including myelosuppression.
Taşdoğan, Ali Muhittin +1 more
core +1 more source
Risk factors analysis and nomogram development for myelosuppression in diffuse large B-cell lymphoma patients undergoing first-line chemotherapy: a dual-centre retrospective cohort study [PDF]
PeerJObjective The primary objective of this research was to examine the characteristics of myelosuppression following first-line chemotherapy in patients suffering from diffuse large B-cell lymphoma (DLBCL).
Xuexing Wang +6 more
doaj +2 more sources
Cancer Medicine, 2023 Purpose Whether the addition of tislelizumab to gemcitabine and cisplatin (GC) chemotherapy increases the incidence of myelosuppression has not been well established.
Zhimin Gao +8 more
doaj +1 more source
Effect of Zishenshengxue capsule on myelosuppression in mice induced by cyclophosphamide [PDF]
, 2013 ObjectiveTo explore the inhibitory effect of Zishenshengxue capsule (ZSC) on myelosuppression in mice induced by cyclophosphamide.MethodsKunming mice were randomly assigned into a control group, myelosuppression group, or groups for mice with ...
Li, Wei, Li, Xinna, Zhao, Ying
core +1 more source
Cancer Medicine, 2023 Background Myelosuppression is a major dose‐limiting complication of chemotherapy for patients with extensive‐stage small cell lung cancer (ES‐SCLC). The objective was to describe the burden of myelosuppression, treatment patterns, and supportive care ...
Lowell Hart +8 more
doaj +1 more source
Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases. [PDF]
, 2016 OBJECTIVE:Severe myelosuppression is a serious concern in the management of rheumatic disease patients receiving methotrexate (MTX) therapy. This study was intended to explore factors associated with the development of MTX-related myelosuppression and ...
Toshiro Kawakita +7 more
core +1 more source
, 2022 Myelosuppression, a potential adverse reaction of nafcillin and rifampin, is rarely documented in pediatric populations. The objective of this study is to describe the incidence of myelosuppression in pediatric patients receiving nafcillin or a ...
Jolly Kuriakose +5 more
core +1 more source